Physician profile
Daniel C Beck
NPI 1992287544
$113,802.97
in general payments reported to CMS, 2019-2025
23 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,999 · 2022: $18K · 2023: $41K · 2024: $25K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Travel and Lodging: $14K · Food and Beverage: $4,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,655.00 |
| Travel and Lodging | $13,503.53 |
| Food and Beverage | $4,517.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $111,209.57 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $515.20 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $399.81 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $394.24 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $216.25 | 2021-2025 | Nuedexta, Rexulti, Abilify Maintena |
| Abbvie INC. | $162.43 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $153.55 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $144.28 | 2023 | Austedo Xr, Uzedy, Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.37 | 2024 | Xifaxan |
| Lundbeck LLC | $100.69 | 2021-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $61.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $43.64 | 2021 | |
| Merck Sharp & Dohme LLC | $40.01 | 2021 | |
| Novo Nordisk INC | $36.16 | 2021-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $33.38 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $33.10 | 2025 | Fanapt |
| Indivior INC. | $27.60 | 2023 | Perseris |
| Lilly USA, LLC | $26.76 | 2023 | Trulicity |
| Owp Pharmaceuticals, INC. | $22.16 | 2024 | Subvenite |
| Daiichi Sankyo INC. | $17.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.25 | 2025 | Breztri |
| Sumitomo Pharma America, INC. | $14.74 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.